►Trethera is a clinical-stage biopharmaceutical company developing cancer treatments for orphan blood cancers with high unmet needs. The Company is led by an experienced drug development team and was founded by highly recognized UCLA faculty successful in bringing medical products to market. Focusing on the pathways controlling cancer nucleotide metabolism led to the development of TRE-515, a first-in-class inhibitor of deoxycytidine kinase (dCK) that is targeted to enter a Phase 1 clinical study in H1 2018.

►Trethera is capitalizing on novel insights into the metabolic demands and vulnerabilities of cancer during rapid DNA replication and is developing small molecule compounds to precisely target these pathways.

►By targeting multiple pathways using rationally-designed combinations of drugs, Trethera’s therapeutic approaches are designed to improve efficacy and overcome the limitations of previous single agent therapies.